The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. CAMP4 Therapeutics Corp shares valued at $1,999,999 were purchased by Polaris Management Co. VII, L. on Sep 11 ’25. At $1.53 per share, Polaris Management Co. VII, L. acquired 1,307,189 shares. The insider’s holdings grew to 2,825,500 shares worth approximately $7.85 million following the completion of this transaction.
Also, Nashat Amir purchased 1,307,189 shares, netting a total of over 1,999,999 in proceeds. Following the buying of shares at $1.53 each, the insider now holds 2,825,500 shares.
Before that, Maricich Yuri had added 6,060 shares to its account. In a trade valued at $9,999, the Chief Medical Officer bought CAMP4 Therapeutics Corp shares for $1.65 each. Upon closing the transaction, the insider’s holdings increased to 6,060 shares, worth approximately $16846.8.
As published in their initiating research note from Wedbush on May 27, 2025, CAMP4 Therapeutics Corp [CAMP] has been an Outperform and the price target has been revised to $8. Analysts at William Blair started covering the stock with ‘”an Outperform”‘ outlook in a report released in early November. As of November 05, 2024, Piper Sandler has initiated its “an Overweight” rating for CAMP. Earlier on November 05, 2024, JP Morgan initiated its rating. Their recommendation was “an Overweight” for CAMP stock.
Analyzing CAMP Stock Performance
On last trading session, CAMP4 Therapeutics Corp [NASDAQ: CAMP] plunged -0.36% to $2.78. The stock’s lowest price that day was $2.5, but it reached a high of $2.95 in the same session. During the last five days, there has been a surge of approximately 87.84%.
Support And Resistance Levels for CAMP4 Therapeutics Corp (CAMP)
According to the 24-hour chart, there is a support level at 2.54, which, if violated, would cause prices to drop to 2.29. In the upper region, resistance lies at 2.99. The next price resistance is at 3.19. RSI (Relative Strength Index) is 79.95 on the 14-day chart, showing overbought technical sentiment.
Is CAMP4 Therapeutics Corp subject to short interest?
Stocks of CAMP4 Therapeutics Corp saw a sharp steep in short interest on 2025-08-29 dropping by 29241.0 shares to 0.22 million. Data from Yahoo Finance shows that the short interest on 2025-07-31 was 0.25 million shares. A decline of -13.39% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 2.34 of the overall float, the days-to-cover ratio (short ratio) decline to 2.34.
Which companies own the most shares of CAMP4 Therapeutics Corp (CAMP)?
In terms of CAMP4 Therapeutics Corp share price expectations, FactSet research, analysts set an average price target of 13.5 in the next 12 months, up nearly 383.87% from the previous closing price of $2.79. Analysts anticipate CAMP4 Therapeutics Corp stock to reach 18 by 2025, with the lowest price target being 5. In spite of this, 4 analysts ranked CAMP4 Therapeutics Corp stock as Buy at the end of 2025.
